Table 3.
Univariate analysis of factors affecting progression-free survival (n = 50).
| Variables | Category | Univariate analysis | ||
|---|---|---|---|---|
| HR | 95% CI | P-value | ||
| Age (years) | ≥65 vs. <65 | 1.13 | 0.47–2.71 | 0.79 |
| Sex | Female vs. Male | 1.88 | 0.94–3.76 | 0.08 |
| ECOG PS | ≥2 vs. 0–1 | 1.57 | 0.67–3.65 | 0.30 |
| Brain metastasis | Yes vs. No | 0.48 | 0.23–1.02 | 0.06 |
| Liver metastasis | Yes vs. No | 1.19 | 0.59–2.41 | 0.63 |
| Bone metastasis | Yes vs. No | 1.66 | 0.86–3.18 | 0.13 |
| NLR | High vs. Low | 1.29 | 0.45–3.67 | 0.64 |
| PLR | High vs. Low | 1.23 | 0.59–2.56 | 0.58 |
| Total BTS | Large vs. Small | 1.44 | 0.55–3.75 | 0.46 |
BTS, baseline tumor size; CI, confidential interval; ECOG PS, Eastern Cooperative Oncology Group performance status; ES, extensive-stage; HR, hazard ratio; LS, limited-stage; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio